Quantcast
Last updated on April 16, 2014 at 5:49 EDT

Latest Monoclonal antibodies Stories

2013-11-25 08:26:38

TARRYTOWN, N.Y., Nov. 25, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Leonard S. Schleifer, M.D., Ph.D., President, and Chief Executive Officer of Regeneron, and George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories, have been named "Management Team of The Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading...

2013-11-21 23:28:43

Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, and Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, today announced the signing of a product development agreement. Somerset, NJ, and Austin, TX (PRWEB) November 21, 2013 Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, and Catalent Pharma Solutions, the global leader in drug...

2013-11-22 00:20:42

Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints PARIS and TARRYTOWN, N.Y., Nov. 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the SARIL-RA-MOBILITY Phase 3 clinical trial in adult patients with active rheumatoid arthritis (RA) who were inadequate responders to methotrexate (MTX) therapy, sarilumab (the first fully-human anti-IL-6R monoclonal antibody) treatment in...

2013-11-21 08:26:52

Anti-leukotriene antibodies were generated with ImmuneY2(TM), Lpath's drug-discovery engine SAN DIEGO, Nov. 21, 2013 /PRNewswire/ -- Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, has used its proprietary discovery technology to generate several monoclonal antibody product candidates targeting the leukotriene family of bioactive lipids. Leukotrienes are implicated in numerous inflammatory processes. The lead antibody, which binds to and neutralizes...

2013-11-21 04:22:15

Tanabe Research Laboratories and Mitsubishi Tanabe Pharma Nominate First Bispecific FynomAb® for Preclinical Development and Exercise an Option for a Second Bispecific FynomAb Program ZURICH-SCHLIEREN, Switzerland and SAN DIEGO, Nov. 21, 2013 /PRNewswire/ -- Covagen and Tanabe Research Laboratories U.S.A, Inc. (TRL), a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they expanded their strategic research collaboration. MTPC and TRL have...

2013-11-18 12:29:12

DALLAS, November 18, 2013 /PRNewswire/ -- The "Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018", provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global Biosimilars Market...

2013-11-14 12:26:27

Compared to One Year Ago, TNF-alpha Inhibitors Have Seen Growth in All Three Lines of Therapy, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has seen growth in all three lines of therapy, particularly the second- and...

2013-11-12 23:27:58

Monoclonal antibodies specific to Rift Valley Fever Virus developed by Maine Biotechnology Services, in partnership with the USDA-Agricultural Research Service, are now available for sampling. The antibodies were developed to support ongoing research efforts to advance adequate vaccine and rapid detection methods. Portland, Maine (PRWEB) November 12, 2013 In July 2012, Maine Biotechnology Services entered into a partnership with Dr. Scott McVey, supervisor of the USDA-Agricultural...

2013-11-12 23:25:17

Reportbuyer.com just published a new market research report: Psoriasis Treatment: World Drug Market 2013-2023. London (PRWEB) November 12, 2013 Report Details Psoriasis drugs - this new study shows you R&D, opportunities, and potential revenues What's the future of treating psoriasis? Visiongain's new report gives you revenue predictions from 2013, helping you stay ahead. There you see financial results, R&D trends, opportunities, and potential revenues. Avoid falling...

2013-11-07 23:34:32

A new randomized, controlled trial(RCT) is the fourth RCT to provide evidence for the efficacy of etanercept for intervertebral disc-related pain. The first human data regarding the effectiveness of etanercept for sciatica was reported by the Institute of Neurological Recovery more than a decade earlier. Los Angeles, California (PRWEB) November 07, 2013 A new randomized clinical trial (RCT) published in the November 1, 2013 issue of the journal Spine (1) provides new evidence for the...